Arrowhead Research | ARWR - 税前利润



金融业
股票价格
USD
资产
USD 2.11B
现金及等价物
USD 19.69M
流动资产
USD 1.67B
流动负债
USD 283.35M
债务
USD 983.69M
EBIT
USD -154.34M
EBITDA
USD -147.68M
员工
711
EPS每股收益
USD -1.36
股本和储备
USD 465.53M
销售毛利
USD 75.25M
债务利息支出
USD 24.56M
利息收入
USD 16.94M
贷款资金
USD 824.07M
市值
USD 8.18B
净收入
USD -194.28M
营业费用
USD 245.35M
营业利润
USD -170.09M
普通股股本
USD 141.14M
PE价格收益
39.19
税前利润
USD -178.91M
销售收入
USD 75.23M
销售和管理费用
USD 46.63M
股票
USD -173.09M
贸易债权人
USD 27.78M
应收帐款人
USD 8.56M


税前利润 更改 日
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
Alnylam Pharmaceuticals USD 177.81M 43.85M 2026-06
Anika Therapeutics USD 764K 3M 2025-12
Arrowhead Research USD -178.9M 41.34M 2026-06
Heron Therapeutics USD -2.95M 14.54M 2025-12
Incyte USD 751.51M 407.91M 2026-06
Ionis Pharmaceuticals USD -114M 21M 2026-06
Ligand Pharmaceuticals USD -24.26M 81.04M 2026-03
Merck USD -3.53B 6.95B 2026-03
Moderna USD -1.33B 535M 2026-03
Nektar Therapeutics USD -43.09M 8.39M 2026-03
Novartis USD 4.27B 430M 2026-06
Sarepta Therapeutics USD -1.75M 344.92M 2026-06
TG Therapeutics USD 10.23M 10.13M 2026-06
Ultragenyx Pharmaceutical USD -91M 93M 2026-06
Vertex Pharmaceuticals USD 1.39B 138.9M 2026-06
Xencor USD -21.92M 106.72M 2026-06